In the News
Francis Medical Featured in Articles and Press Releases
Francis Medical Appoints Andrew Cleeland to Board of Directors
January 26, 2023: Francis Medical has appointed to its board of directors Andrew Cleeland, a leader with extensive experience in healthcare innovation and the development and deployment of new medical technologies.
OnFocus Podcast: Michael Hoey
Francis Medical Founder and Chief Technology Officer, Michael Hoey, joins The Focal Therapy Clinic OnFocus podcast to discuss a new approach to focal therapy, water vapor therapy, and its adoption into medical practice.
Press Release: Francis Medical Announces Close of $55 Million Series B Equity Financing
September 15, 2021: Francis Medical today announced the completion of the company’s $55.0 million Series B equity financing. The company plans to use the Series B proceeds to fund the development of its proprietary prostate cancer treatment through FDA 510(k) approval, which includes a pivotal clinical study (VAPOR 2) for the management of prostate cancer, scheduled to begin enrollment in August 2022.
Press Release: Francis Medical Announces Positive Data from VAPOR 1 IDE Study for Water Vapor Ablation of Prostate Cancer
June 8, 2021: Francis Medical announces positive data from its Vapor 1 IDE Study for water vapor ablation of prostate cancer. These promising results support the intent of this therapy to manage clinically significant disease while decreasing morbidities associated with currently used prostate cancer treatments.
For the Record with Michael Hoey, Founder and CTO, Francis Medical
In an interview for Medical Alley's "For the Record," the founder and CTO of Francis Medical, Michael Hoey, shares why he sought a more compassionate approach for treating prostate cancer and how he discovered water vapor technology. He also gives a window into how things are progressing at Francis Medical...
Enhancing Quality of Life
“The two things in life that make us all equal are time and health. Once spent, there is no coming back. Francis Medical saves both of these most precious of resources to the fullest in managing prostate cancer.”
DR DAVID ADAIR, MD, MBA
BOARD MEMBER, FRANCIS MEDICAL
DIRECTOR, SOLAS BIOVENTURES